Medicine
Avtozma 162 mg/0.9 mL injection
Avtozma 162 mg/0.9 mL injection is a prescription medicine containing Tocilizumab for subcutaneous use, marketed by Celltrion, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
If necessary, the prefilled syringe or autoinjector may be returned to the…
Key facts
- Active ingredient (INN)
- Tocilizumab
- Brand
- Avtozma
- Strength
- 162 mg/0.9 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 0.9 mL, 4 syringes of 0.9 mL, 12 syringes of 0.9 mL and 3 more
- Marketing authorisation holder
- Celltrion
- Manufacturer
- Celltrion
- Origin register
- US FDA, United States
- Storage
- If necessary, the prefilled syringe or autoinjector may be returned to the refrigerator once within these 3 weeks and stored refrigerated until the expiry date.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC07 Tocilizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 February 2026
- Identifiers
- RxCUI 2705425, 2705432, 2705435 +7DailyMed set ID 581c288f-8015-40ef-a4c3-683c96db193dNDC 72606-045Application BLA761498
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe, glass in 1 carton / .9 mL in 1 syringe, glass | 72606-045-01 | Celltrion | 1 February 2026 |
| 4 syringe, glass in 1 carton / .9 mL in 1 syringe, glass | 72606-045-02 | Celltrion | 1 February 2026 |
| 12 syringe, glass in 1 carton / .9 mL in 1 syringe, glass | 72606-045-03 | Celltrion | 1 February 2026 |
| 1 syringe, glass in 1 carton / .9 mL in 1 syringe, glass | 72606-045-04 | Celltrion | 1 February 2026 |
| 4 syringe, glass in 1 carton / .9 mL in 1 syringe, glass | 72606-045-05 | Celltrion | 1 February 2026 |
| 12 syringe, glass in 1 carton / .9 mL in 1 syringe, glass | 72606-045-06 | Celltrion | 1 February 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tocilizumab 162 mg/0.9 mL injection.
- Tyenne 162 mg/0.9 mL injectionAvailable on requestFresenius KabiUS FDA2 packs Cold chain
- Tyenne 162 mg/0.9 mL injectionAvailable on requestFresenius KabiUS FDA2 packs Cold chain
- Actemra 162 mg/0.9 mL injectionAvailable on requestGenentechUS FDA1 pack Cold chain
- Actemra ACTPen 162 mg/0.9 mL injectionAvailable on requestGenentechUS FDA1 pack Cold chain
Other strengths and forms of Tocilizumab
Clinical summary
Tocilizumab is an interleukin-6 receptor antagonist indicated for treatment of rheumatoid Arthritis (RA), among other approved uses. It is available as injection for intravenous and subcutaneous use. MedsAcross supplies Tocilizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TocilizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- ACTEMRA prescribing information (Genentech) · U.S. National Library of Medicine, DailyMed
- RoActemra: European public assessment report (EPAR) · European Medicines Agency
- Avtozma: European public assessment report (EPAR) · European Medicines Agency
Need Avtozma 162 mg/0.9 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.